A Novel Approach to Advancing Breast Cancer Therapy

Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes. In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics. Olema Terapeutics is developing new treatment options designed to improve outcomes for women with metastatic breast cancer. The company’s lead investigational drug is OP-1250. This drug is a is a novel agent with combined activity as both an advanced complete estrogen receptor antagonist, and a selective estrogen receptor degrader. This approach is expected to drive deeper, more durable responses than currently available therapies. OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), in both monotherapy and combination settings. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program. For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. Clinical trials - Phase 1b Combo w/ Ribociclib and Alpelisib | NCT05508906 - A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients - NCT05266105 -A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer - NCT04505826